Chimeric Therapeutics
- Short interest
- 0.00%
- −0.13 pp 30d
- as of 11 May 2026
- Reported shorts
- 1
- Shares on issue
- 51.822M
Chimeric Therapeutics (CHM) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $0M (source: ASX (Markit))vs $4.0M (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- −$18.8MM (source: ASX (Markit))vs −$10.4M (FY25)
- ASX (Markit), as at 14 Oct 2026
- EPS (diluted)
- −$0.61T (source: Derived: trailing 12 months at year end)vs −$0.77 (FY25)
- Derived: trailing 12 months at year end, as at 14 Oct 2026
- Rev YoY
- n/mFY
- EPS YoY
- n/aTTM
- ASX (Markit)
- Derived: trailing 12 months at year end
Summary of FY2026 Annual Report, creditor update and Board changes, 1 Oct 2026
Chimeric Therapeutics has not filed its FY2026 financial statements by the due date, leading to a trading suspension. The company reports a net asset deficiency of approximately $7.7 million and is negotiating with creditors to settle liabilities, with no binding recapitalisation proposal yet received. No dividend has been declared, and the company expects its securities to remain suspended until audited financials are lodged.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 14 Oct 2026
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- n/a
- FCF margin
- n/a
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Source: ASX (Markit), as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $0M (source: ASX (Markit)) | $4.0M | $0M (source: ASX (Markit)) | $0M (source: ASX (Markit)) |
| Gross profit | n/a | $3.1M | n/a | n/a |
| Operating income | n/a | −$15.1M | −$21.0M | −$29.5M |
| EBITDA | n/a | −$9.1M | −$11.2M | −$23.7M |
| EBIT | n/a | −$10.1M | −$12.2M | −$24.6M |
| Interest expense | n/a | $211.0K | $331.8K | $773.8K |
| Pretax income | n/a | −$10.3M | −$12.5M | −$25.4M |
| Tax | n/a | $110.8K | $9.7K | $92.8K |
| NPAT | −$18.8MM (source: ASX (Markit)) | −$10.4M | −$12.5M | −$25.5M |
| Net interest income | n/a | −$163.0K | −$210.5K | −$746.3K |
| EPS basic | −$0.61T (source: Derived: trailing 12 months at year end) | −$0.77 | −$1.71 | −$5.61 |
| EPS diluted | −$0.61T (source: Derived: trailing 12 months at year end) | −$0.77 | −$1.71 | −$5.61 |
| Shares | n/a | 20.2M | 9.2M | 5.3M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- FY2026 Annual Report, creditor update and Board changesAnnual Report1 Oct 2026via asx_announcements
- Appendix 4E and Preliminary Final ReportAnnual Results31 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Apr 2026via asx_announcements
- Half Year Report and Appendix 4D 31 December 2025Half Year Results27 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report28 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report31 Oct 2025via asx_announcements
- Appendix 4E and Annual ReportAnnual Results29 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report29 Jul 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report23 Apr 2025via asx_announcements
Showing 10 of 31 reports